Compare Amphastar Pharmaceuticals Inc (AMPH) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Newmont Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Newmont Corporation trades at $117.65 (market cap $123.56B). The key difference: Newmont Corporation is far larger — about 143× Amphastar Pharmaceuticals Inc's market cap, and Newmont Corporation pays a 0.89% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NEM | |
|---|---|---|
Market Cap | $863.95M | $123.56B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $131.95 |
52-Week Low | $16.87 | $67.38 |
Enterprise Value | $1.26B | $120.14B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Newmont Corporation (NEM) trades at $112.98, up 7.16% over 24 hours, reflecting strong momentum amid record gold prices. The stock exhibits bullish technical signals with moving averages aligned positively, though oscillators suggest overbought conditions. Fundamentally, the company reported robust earnings, with Q2 2026 EPS of $2.10 beating estimates, and annual revenue growth from $11.9B in 2022 to $22.7B in 2025. Recent news highlights a $1.95B settlement with Barrick Mining, resolving Nevada disputes and enhancing strategic flexibility.
Outlook remains positive with a consensus price target of $133, implying 17.8% upside, supported by 75.7% analyst buy ratings. Key opportunities include strong free cash flow generation and production guidance maintenance. Risks involve potential cost pressures in H2 2026, gold price volatility, and insider stock sales by the CEO and CFO in early August 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
